维普期刊资源整合服务平台（V6.5）

198篇 您的检索式：作者名="Rugo"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	晚期Luminal(HER2阴性)型乳腺癌患者的MDT诊疗显示文摘本文介绍1例激素受体阳性、人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER2)阴性晚期乳腺癌多线内分泌治疗的多学科诊疗过程。该病例有较长的无瘤生存期(10年),初始复发转移肿瘤分布范围广,涉及两肺多发、多处骨骼及颈部锁骨上等区域多发淋巴结转移,经锁骨上转移淋巴结穿刺病理证实,免疫组织化学检测仍为雌激素受体(estrogen receptor,ER)强阳性/HER2阴性,但是孕激素受体(progesterone receptor,PR)仅小区阳性。经过多学科讨论后患者依次一线接受高剂量氟维司群(500 mg,肌注,28 d/次,首月第14天负荷剂量)内分泌治疗,二线选择哌柏西利(125 mg/d,服21 d,休7 d)+来曲唑(2. 5 mg/d),三线接受哌柏西利+氟维司群(同前),其2次进展仅表现为新发淋巴结转移或胸腔积液,并未发现内脏新发病灶或者病灶增大。其一、二线内分泌治疗的无进展生存期(progression free survival,PFS)均为12个月,三线内分泌治疗保留哌柏西利,换用一线的内分泌治疗药物(氟维司群)。临床上,还有全身化疗和局部放疗等选择。由于患者自发病以来一直拒绝接受化疗,术后辅助仅选择阿那曲唑(1 mg/d)辅助内分泌治疗(5年),解救治疗期间同样要求仅选择内分泌治疗。鉴于患者的意愿和肿瘤特征与演变、分子检测与监测,结合MDT专家意见,连续选择内分泌治疗作为解救治疗,取得较长的疾病控制实践,患者维持较好的生活质量。	曹文明邓雪英陈波杜向慧陈占红郑亚兵 Hope Rugo Geraldine M.Jacobson 郑鸿钧王晓稼	2018	实用肿瘤杂志2018，33，6：	6
2	A phase Ⅱ trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer显示文摘	Dickler MN Rugo HS Eberle CA	2008	Clin Cancer Res2008，14，：	1
3	Bevacizumab in the treatment of breast cancer: rationale and current data 显示文摘	Rugo H S	2004	Oncologist2004，9，1：	1
4	A randomized,phase Ⅱ,three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer显示文摘	Rugo HS Campone M Amadori D	2013	Breast Cancer Res Treat2013，139，2：	1
5	Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia显示文摘	RUGO H S RIES C A	1996	Bone Marrow Transplant1996，17，1：	1
6	Leukocyte composition of human breast cancer显示文摘	Ruffell B Au A Rugo H S	2012	Proc Nail Acad Sci U S A2012，109，8：	1
7	TBCRC 001: randomized phase II study of cetuximab in combina- tion with carboplatin in stage IV triple-negative breast can- cer 显示文摘	CAREY LA RUGO HS MARCOM PK	2012	Journal of Clinical Ontology Official Journal of the American Society of Clinical Oncology2012，30，30：	1
8	Phase II study of sunitinib malate, an oral multi-targeted tyrosine kinas inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane 显示文摘	Burstein H J Elias A D Rugo H S	2008	JClin Oncol2008，26，11：	1
9	TBCRC 001:EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2008	J Clin Oncol2008，26，151：	1
10	Phase Ⅰ trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmaeokinetie and clinical results 显示文摘	Rugo HS Herbst RS Liu G	2005	Clin Oncol2005，23，24：	1
11	EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2008	J Clin Oncol2008，26，15：	1
12	Bevacizumab in the treatment of breast cancer:rationale and current data显示文摘		2004	Oncologist2004，1，9：	1
13	Immune microenviron-ments in solid tumors:new targets for therapy 显示文摘	Shiao SL Ganesan AP Rugo HS	2011	Genes Dev2011，25，24：	1
14	Phase II study of the an- tibody drug conjugate trastuzumab- DM1 for the treatment of hu- man epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2--directed therapy显示文摘	Burris HA 3rd Rugo HS Vukelja SJ	2011	J Clin Oncol2011，29，4：	1
15	Phase II study of suni- tinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane 显示文摘	Burstein H J Elias AD Rugo HS	2008	J Clin Oncol2008，26，11：	1
16	Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2- directed therapy 显示文摘	BURRIS HR RUGO HS VUKLJA SJ et o1	2011	J Clin Oncol2011，29，4：	1
17	TBCRC 001 : randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer 显示文摘	Carey LA Rugo HS Marcom PK	2012	J Clin Oncol2012，30，21：	1
18	Phase II study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane显示文摘	Burstein H J Elias AD Rugo HS	2008	J Clin Oncol2008，26，11：	1
19	Phase Ⅲ trial of capecitabine (Xeloda○ R) plus bevacizumab (AvastinTM) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane显示文摘	Miller KD Rugo HS Cobleigh MA	2002	Breast Cancer Res Treat2002，76，1：	1
20	Phase Ⅱ trial of erlotinib ( OSI-774), an epidermal growth factor receptor ( EGFR ) -Wrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor- VEGF) ,in patients ( pts ) with metastatic brast cancer ( MBC ) 显示文摘	Dickler M Rugo H CaraveUi J	2004	Proc Am Soc Clin Oneol2004，23，：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示